Results 61 to 70 of about 1,144,647 (289)
Journal of Pharmacological Sciences, 2006 UTP causes interleukin (IL)-6 production via mRNA expression through P2Y2/P2Y4 receptors in human HaCaT keratinocytes. In the present study, we analyzed the mechanism of UTP-induced IL-6 production in these cells.
Daisaku Kobayashi +2 more
doaj +1 more source
Dupilumab: Basic aspects and applications to allergic diseases
Allergology International, 2020 Interleukin (IL)-4 and IL-13, signature type 2 cytokines, exert their actions by binding to two types of receptors sharing the IL-4R α chain (IL-4Rα).
Kazuto Matsunaga +4 more
doaj +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is a progressive neuromuscular disorder with no approved treatments. Identifying reliable biomarkers is critical to monitor disease severity, activity, and progression. Interleukin‐6 (IL‐6) has been proposed as a candidate biomarker, but longitudinal validation is limited ...
Jonathan Pini +13 more
wiley +1 more source
Interleukin-2 signalling is modulated by a labile disulfide bond in the CD132 chain of its receptor [PDF]
Open Biology, 2012 Certain disulfide bonds present in leucocyte membrane proteins are labile and can be reduced in inflammation. This can cause structural changes that result in downstream functional effects, for example, in integrin activation.
Clive Metcalfe +2 more
doaj +1 more source
Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease.
British Journal of Cancer, 1987 The mechanisms leading to the complex clinico-patholological picture in Hodgkin's Disease (HD) are poorly understood. In particular, the intimate nature and meaning of immunological abnormalities extensively reported in this disease, and the affiliation ...
G. Pizzolo +9 more
semanticscholar +1 more source
Frailty Exacerbates Disability in Progressive Multiple Sclerosis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background To evaluate frailty in severe progressive multiple sclerosis (PMS) and to investigate the underlying mechanisms. Methods This prospective, cross‐sectional, multicenter study enrolled a late severe PMS group requiring skilled nursing (n = 53) and an age, sex, and disease duration‐matched control PMS group (n = 53).
Taylor R. Wicks +10 more
wiley +1 more source
Roles of muscarinic acetylcholine receptors in interleukin-2 synthesis in lymphocytes.
, 2001 Receptors for many neurotransmitters including catecholamines and acetylcholine (ACh) have been detected on the cell surface of lymphocytes. It has been demonstrated that a human T cell line synthesizes ACh and suggested that ACh may be an autacoid ...
Y. Okuma, Y. Nomura
semanticscholar +1 more source
Beta-adrenergic-receptor-mediated suppression of interleukin 2 receptors in human lymphocytes.
Journal of Immunology, 1987 Adrenergic receptor agonists are known to attenuate the proliferative response of human lymphocytes after activation; however, their mechanism of action is unknown.
R. Feldman, G. Hunninghake, W. McArdle
semanticscholar +1 more source
Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin +2 more
wiley +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela +13 more
wiley +1 more source